search
Back to results

An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects (APOLLOE4)

Primary Purpose

Early Alzheimer's Disease

Status
Active
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Experimental: ALZ-801
Placebo Comparator: Placebo
Sponsored by
Alzheon Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Early Alzheimer's Disease

Eligibility Criteria

50 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Clinical diagnosis of MCI or Mild Dementia due to AD consistent with the National Institute on Aging-Alzheimer's Association (NIA-AA) Working Group Criteria.
  • Homozygous for the ε4 allele of the apolipoprotein E gene (APOE4/4).
  • MMSE score at Screening of 22 to 30 (inclusive).
  • CDR - Global score of 0.5 or 1 and CDR Memory Box Score of ≥ 0.5.
  • RBANS delayed memory index score ≤ 85.
  • Evidence of progressive memory loss over the last 12 months per investigator assessment

Exclusion Criteria:

  • Brain magnetic resonance imaging (MRI) indicative of significant abnormality per central reader, other than AD related atrophy. Computed tomography (CT) scan acceptable for subjects who can not undergo MRI.
  • Diagnosis of neurodegenerative disorder other than AD.
  • Diagnosis of major depressive disorder (MDD) within one year prior to screening.
  • Currently taking memantine or has taken memantine within 12 weeks prior to the Screening - Part 2 Visit.
  • History of suicidal behavior within one year prior to screening or has ongoing suicidal ideation.
  • History of seizures, excluding febrile seizures of childhood or a single distant seizure (> 10 years).
  • Medically confirmed history of recent cerebral infarct or transient ischemic attack within one year prior to screening.

Sites / Locations

  • Xenoscience
  • CCT Research
  • Banner Sun Health Research Institute
  • ATP Clinical Research
  • Tilda Research
  • UCSD Shiley-Marcos Alzheimer's Disease Research Center
  • Torrance Clinical Research Institute
  • Collaborative Neuroscience Research
  • Stanford University
  • SC3 Research Group
  • Sutter Neuroscience Institute
  • The Neuron Clinic
  • JEM Headlands Research Institute
  • Bradenton Research Center
  • Galiz Research
  • Alphab Global Research
  • Charter Research
  • Mount Sinai Medical Center
  • Miami Jewish Health
  • Elite Clinical Research
  • Aqualane Clinical Research
  • K2 Medical Research
  • Headlands Research Orlando
  • Advanced Research Consultants
  • Quantum Laboratories
  • Progressive Medical Research
  • Alzheimer's Research and Treatment Center
  • Alzheimer's Research and Treatment Center
  • Premiere Research Institute
  • Charter Research
  • Columbus Memory Center
  • NeuroStudies
  • Fort Wayne Neurological Center
  • Louisiana State University Health Sciences Center (LSUHSC)
  • Donald S Marks, MD, PC
  • Wake Research - Clinical Research Center of Nevada
  • Advanced Memory Research Center
  • Neurological Associates of Albany
  • NYU Alzheimer's Disease Research Center
  • Kline Institute for Psychiatric Research
  • University of Rochester Medical Center
  • Richmond Behavioral Associates
  • Triad Clinical Trials
  • AMC Research
  • NeuroScience Research Center
  • Neurology Diagnostics
  • IPS Research Company
  • Center for Cognitive Health
  • Abington Neurological Associates
  • Lehigh Center for Clinical Research
  • Rhode Island Mood & Memory Research Institute
  • Vanderbilt University Medical Center
  • UT Health Science Center at Houston
  • Re:Cognition Health
  • Northwest Clinical Research Center
  • Medical College of Wisconsin
  • Okanagan Clinical Trials
  • True North Clinical Research
  • True North Clinical Research
  • Ottawa Memory Clinic
  • Kawartha Centre
  • Toronto Memory Program
  • Clinique de la Mémoire de l'Outaouais
  • Medica 111
  • Fakultní nemocnice u sv. Anny v Brně (St. Anne's University Hospital)
  • Neuropsychiatrie s.r.o.
  • Vestra Clinics
  • Hospices Civils de Lyon - Institut du vieillissement
  • Centre Hospitalier Universitaire de Marseille - Hôpital de la Timone
  • CHU De Montpellier - Hôpital Gui De Chauliac
  • Groupe Hospitalier Saint-Louis, Lariboisière, Fernand Widal
  • Centre Hospitalier Universitaire de Rouen
  • Centre Mémoire de Ressources et de Recherche (CM2R) des Hôpitaux Universitaires de Strasbourg
  • CHU Toulouse - Centre de Recherche Clinique du Gérontopôle
  • Uniklinik RWTH Aachen Medizinische Klinik III
  • Klinikum der Universitaet Muenchen Innenstadt
  • Klinik fuer Psychiatrie und Psychotherapie
  • Studienzentrum Nord-West
  • Memory Clinic Geriatric Department Landspitali University Hospital
  • Brain Research Center Amsterdam
  • Brain Research Center Den Bosch
  • Brain Research Center Zwolle
  • Fundacia ACE - Institut Catala de Neurociencies Aplicadas
  • Clinica Universidad de Navarra
  • Hospital Clinico San Carlos
  • Clinica Universidad de Navarra
  • Hospital Universitari MutuaTerrassa
  • Centro Hospital Universitario Dr. Preset
  • Re:Cognition Health
  • Re:Cognition Health
  • Re:Cognition Health
  • St. Pancras Clinical Research
  • Re:Cognition Health
  • Glasgow Memory Clinic
  • Re:Cognition Health
  • Re:Cognition Health

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

ALZ-801

Placebo

Arm Description

ALZ-801 265 mg BID tablet orally. Subjects will receive placebo in the morning and one table of ALZ-801 265mg tablet in the evening during the first two weeks of the study; thereafter, they will receive a 265mg tablet BID.

Subjects in the placebo treatment arm will receive placebo tablets BID throughout the study

Outcomes

Primary Outcome Measures

Primary cognitive efficacy endpoint
Change from baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale 13 (ADAS-cog 13) scores at 78 weeks
Incidence, Nature, and Severity of Treatment Emergent Adverse events (TEAE)
Safety and tolerability as measured by incidence, nature and severity of treatment emergent adverse events (TEAE), serious TEAE, and TEAE leading to withdrawal.
Primary fluid biomarker endpoint 1
Change from baseline in cerebrospinal fluid p-tau181 levels in sub-study
Primary fluid biomarker endpoint 2
Change from baseline in plasma p-tau181 levels
Primary imaging biomarker endpoint
Change from baseline in total hippocampal volume (mm3) as measured by Magnetic Resonance Imaging (MRI)

Secondary Outcome Measures

Functional assessment 1
Change from baseline in Amsterdam - Instrumental Activities of Daily Living scores
Global assessment
Change from baseline in Clinical Dementia Rating - Sum of Boxes (CDR-SB) scores
Functional assessment 2
Change from baseline in Disability Assessment for Dementia (DAD)scores

Full Information

First Posted
February 22, 2021
Last Updated
March 25, 2023
Sponsor
Alzheon Inc.
Collaborators
National Institute on Aging (NIA)
search

1. Study Identification

Unique Protocol Identification Number
NCT04770220
Brief Title
An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects
Acronym
APOLLOE4
Official Title
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy, Safety and Biomarker Effects of ALZ-801 in Subjects With Early Alzheimer's Disease and APOE4/4 Genotype
Study Type
Interventional

2. Study Status

Record Verification Date
March 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
May 19, 2021 (Actual)
Primary Completion Date
May 31, 2024 (Anticipated)
Study Completion Date
June 30, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Alzheon Inc.
Collaborators
National Institute on Aging (NIA)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study is being conducted to evaluate the safety and efficacy of ALZ-801 in Early Alzheimer's disease (AD) subjects with the APOE4/4 genotype. This is a double-blind, randomized trial with one dose of ALZ-801 compared to placebo.
Detailed Description
This is a multi-center, double-blind study that will evaluate 265 mg BID of ALZ-801, an oral tablet, over 78 weeks as a treatment for subjects (50-80 years old) with Early AD who are homozygous for the ε4 allele of the apolipoprotein gene (APOE4 homozygous or APOE4/4). The primary efficacy outcome assessment is a measure of cognition (ADAS-cog 13). Additional measures of global and functional impairments will also be assessed. Imaging and soluble biomarkers of AD and neurodegeneration will be measured and a sub-study to evaluate cerebrospinal fluid (CSF) biomarkers is also included.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Early Alzheimer's Disease

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Model Description
This is a multi-center Phase 3, randomized, double-blind, placebo-controlled, parallel-group study.
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Allocation
Randomized
Enrollment
300 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
ALZ-801
Arm Type
Experimental
Arm Description
ALZ-801 265 mg BID tablet orally. Subjects will receive placebo in the morning and one table of ALZ-801 265mg tablet in the evening during the first two weeks of the study; thereafter, they will receive a 265mg tablet BID.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Subjects in the placebo treatment arm will receive placebo tablets BID throughout the study
Intervention Type
Drug
Intervention Name(s)
Experimental: ALZ-801
Intervention Description
ALZ-801 tablet 265 mg BID
Intervention Type
Drug
Intervention Name(s)
Placebo Comparator: Placebo
Intervention Description
Placebo tablet BID
Primary Outcome Measure Information:
Title
Primary cognitive efficacy endpoint
Description
Change from baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale 13 (ADAS-cog 13) scores at 78 weeks
Time Frame
Week 78
Title
Incidence, Nature, and Severity of Treatment Emergent Adverse events (TEAE)
Description
Safety and tolerability as measured by incidence, nature and severity of treatment emergent adverse events (TEAE), serious TEAE, and TEAE leading to withdrawal.
Time Frame
Week 78
Title
Primary fluid biomarker endpoint 1
Description
Change from baseline in cerebrospinal fluid p-tau181 levels in sub-study
Time Frame
Week 78
Title
Primary fluid biomarker endpoint 2
Description
Change from baseline in plasma p-tau181 levels
Time Frame
Week 78
Title
Primary imaging biomarker endpoint
Description
Change from baseline in total hippocampal volume (mm3) as measured by Magnetic Resonance Imaging (MRI)
Time Frame
Week 78
Secondary Outcome Measure Information:
Title
Functional assessment 1
Description
Change from baseline in Amsterdam - Instrumental Activities of Daily Living scores
Time Frame
Week 78
Title
Global assessment
Description
Change from baseline in Clinical Dementia Rating - Sum of Boxes (CDR-SB) scores
Time Frame
Week 78
Title
Functional assessment 2
Description
Change from baseline in Disability Assessment for Dementia (DAD)scores
Time Frame
Week 78

10. Eligibility

Sex
All
Minimum Age & Unit of Time
50 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Clinical diagnosis of MCI or Mild Dementia due to AD consistent with the National Institute on Aging-Alzheimer's Association (NIA-AA) Working Group Criteria. Homozygous for the ε4 allele of the apolipoprotein E gene (APOE4/4). MMSE score at Screening of 22 to 30 (inclusive). CDR - Global score of 0.5 or 1 and CDR Memory Box Score of ≥ 0.5. RBANS delayed memory index score ≤ 85. Evidence of progressive memory loss over the last 12 months per investigator assessment Exclusion Criteria: Brain magnetic resonance imaging (MRI) indicative of significant abnormality per central reader, other than AD related atrophy. Computed tomography (CT) scan acceptable for subjects who cannot undergo MRI. Diagnosis of neurodegenerative disorder other than AD. Diagnosis of major depressive disorder (MDD) within one year prior to screening. Currently taking memantine or has taken memantine within 12 weeks prior to the Baseline Visit. History of suicidal behavior within one year prior to screening or has ongoing suicidal ideation. History of seizures, excluding febrile seizures of childhood or a single distant seizure (> 5 years). Medically confirmed history of recent cerebral infarct or transient ischemic attack within one year prior to screening.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Susan Abushakra, MD
Organizational Affiliation
Alzheon Inc.
Official's Role
Principal Investigator
Facility Information:
Facility Name
Xenoscience
City
Phoenix
State/Province
Arizona
ZIP/Postal Code
85004
Country
United States
Facility Name
CCT Research
City
Scottsdale
State/Province
Arizona
ZIP/Postal Code
85297
Country
United States
Facility Name
Banner Sun Health Research Institute
City
Sun City
State/Province
Arizona
ZIP/Postal Code
85351
Country
United States
Facility Name
ATP Clinical Research
City
Costa Mesa
State/Province
California
ZIP/Postal Code
92626
Country
United States
Facility Name
Tilda Research
City
Irvine
State/Province
California
ZIP/Postal Code
92612
Country
United States
Facility Name
UCSD Shiley-Marcos Alzheimer's Disease Research Center
City
La Jolla
State/Province
California
ZIP/Postal Code
92037
Country
United States
Facility Name
Torrance Clinical Research Institute
City
Lomita
State/Province
California
ZIP/Postal Code
90717
Country
United States
Facility Name
Collaborative Neuroscience Research
City
Long Beach
State/Province
California
ZIP/Postal Code
90806
Country
United States
Facility Name
Stanford University
City
Palo Alto
State/Province
California
ZIP/Postal Code
94304
Country
United States
Facility Name
SC3 Research Group
City
Pasadena
State/Province
California
ZIP/Postal Code
91105
Country
United States
Facility Name
Sutter Neuroscience Institute
City
Sacramento
State/Province
California
ZIP/Postal Code
95816
Country
United States
Facility Name
The Neuron Clinic
City
San Marcos
State/Province
California
ZIP/Postal Code
92069
Country
United States
Facility Name
JEM Headlands Research Institute
City
Atlantis
State/Province
Florida
ZIP/Postal Code
33462
Country
United States
Facility Name
Bradenton Research Center
City
Bradenton
State/Province
Florida
ZIP/Postal Code
34205
Country
United States
Facility Name
Galiz Research
City
Hialeah
State/Province
Florida
ZIP/Postal Code
33016
Country
United States
Facility Name
Alphab Global Research
City
Jupiter
State/Province
Florida
ZIP/Postal Code
33458
Country
United States
Facility Name
Charter Research
City
Lady Lake
State/Province
Florida
ZIP/Postal Code
32159
Country
United States
Facility Name
Mount Sinai Medical Center
City
Miami Beach
State/Province
Florida
ZIP/Postal Code
33140
Country
United States
Facility Name
Miami Jewish Health
City
Miami
State/Province
Florida
ZIP/Postal Code
33137
Country
United States
Facility Name
Elite Clinical Research
City
Miami
State/Province
Florida
ZIP/Postal Code
33144
Country
United States
Facility Name
Aqualane Clinical Research
City
Naples
State/Province
Florida
ZIP/Postal Code
34105
Country
United States
Facility Name
K2 Medical Research
City
Orlando
State/Province
Florida
ZIP/Postal Code
32751
Country
United States
Facility Name
Headlands Research Orlando
City
Orlando
State/Province
Florida
ZIP/Postal Code
32819
Country
United States
Facility Name
Advanced Research Consultants
City
Palm Beach Gardens
State/Province
Florida
ZIP/Postal Code
33410
Country
United States
Facility Name
Quantum Laboratories
City
Pompano Beach
State/Province
Florida
ZIP/Postal Code
33064
Country
United States
Facility Name
Progressive Medical Research
City
Port Orange
State/Province
Florida
ZIP/Postal Code
32127
Country
United States
Facility Name
Alzheimer's Research and Treatment Center
City
Stuart
State/Province
Florida
ZIP/Postal Code
34997
Country
United States
Facility Name
Alzheimer's Research and Treatment Center
City
Wellington
State/Province
Florida
ZIP/Postal Code
33414
Country
United States
Facility Name
Premiere Research Institute
City
West Palm Beach
State/Province
Florida
ZIP/Postal Code
33407
Country
United States
Facility Name
Charter Research
City
Winter Park
State/Province
Florida
ZIP/Postal Code
32792
Country
United States
Facility Name
Columbus Memory Center
City
Columbus
State/Province
Georgia
ZIP/Postal Code
31909
Country
United States
Facility Name
NeuroStudies
City
Decatur
State/Province
Georgia
ZIP/Postal Code
30030
Country
United States
Facility Name
Fort Wayne Neurological Center
City
Fort Wayne
State/Province
Indiana
ZIP/Postal Code
46804
Country
United States
Facility Name
Louisiana State University Health Sciences Center (LSUHSC)
City
Shreveport
State/Province
Louisiana
ZIP/Postal Code
71103
Country
United States
Facility Name
Donald S Marks, MD, PC
City
Plymouth
State/Province
Massachusetts
ZIP/Postal Code
02360
Country
United States
Facility Name
Wake Research - Clinical Research Center of Nevada
City
Las Vegas
State/Province
Nevada
ZIP/Postal Code
89104
Country
United States
Facility Name
Advanced Memory Research Center
City
Toms River
State/Province
New Jersey
ZIP/Postal Code
08755
Country
United States
Facility Name
Neurological Associates of Albany
City
Albany
State/Province
New York
ZIP/Postal Code
12208
Country
United States
Facility Name
NYU Alzheimer's Disease Research Center
City
New York
State/Province
New York
ZIP/Postal Code
10016
Country
United States
Facility Name
Kline Institute for Psychiatric Research
City
Orangeburg
State/Province
New York
ZIP/Postal Code
10962
Country
United States
Facility Name
University of Rochester Medical Center
City
Rochester
State/Province
New York
ZIP/Postal Code
14620
Country
United States
Facility Name
Richmond Behavioral Associates
City
Staten Island
State/Province
New York
ZIP/Postal Code
10312
Country
United States
Facility Name
Triad Clinical Trials
City
Greensboro
State/Province
North Carolina
ZIP/Postal Code
27410
Country
United States
Facility Name
AMC Research
City
Matthews
State/Province
North Carolina
ZIP/Postal Code
28105
Country
United States
Facility Name
NeuroScience Research Center
City
Canton
State/Province
Ohio
ZIP/Postal Code
44718
Country
United States
Facility Name
Neurology Diagnostics
City
Canton
State/Province
Ohio
ZIP/Postal Code
45459
Country
United States
Facility Name
IPS Research Company
City
Oklahoma City
State/Province
Oklahoma
ZIP/Postal Code
73106
Country
United States
Facility Name
Center for Cognitive Health
City
Portland
State/Province
Oregon
ZIP/Postal Code
97225
Country
United States
Facility Name
Abington Neurological Associates
City
Abington
State/Province
Pennsylvania
ZIP/Postal Code
19001
Country
United States
Facility Name
Lehigh Center for Clinical Research
City
Allentown
State/Province
Pennsylvania
ZIP/Postal Code
18104
Country
United States
Facility Name
Rhode Island Mood & Memory Research Institute
City
East Providence
State/Province
Rhode Island
ZIP/Postal Code
02914
Country
United States
Facility Name
Vanderbilt University Medical Center
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37212
Country
United States
Facility Name
UT Health Science Center at Houston
City
Houston
State/Province
Texas
ZIP/Postal Code
77054
Country
United States
Facility Name
Re:Cognition Health
City
Fairfax
State/Province
Virginia
ZIP/Postal Code
22031
Country
United States
Facility Name
Northwest Clinical Research Center
City
Bellevue
State/Province
Washington
ZIP/Postal Code
98007
Country
United States
Facility Name
Medical College of Wisconsin
City
Milwaukee
State/Province
Wisconsin
ZIP/Postal Code
53226
Country
United States
Facility Name
Okanagan Clinical Trials
City
Kelowna
State/Province
British Columbia
ZIP/Postal Code
V1Y 1Z9
Country
Canada
Facility Name
True North Clinical Research
City
Halifax
State/Province
Nova Scotia
ZIP/Postal Code
B3S 1N2
Country
Canada
Facility Name
True North Clinical Research
City
New Minas
State/Province
Nova Scotia
ZIP/Postal Code
B4N 3R7
Country
Canada
Facility Name
Ottawa Memory Clinic
City
Ottawa
State/Province
Ontario
ZIP/Postal Code
K1Z 1G3
Country
Canada
Facility Name
Kawartha Centre
City
Peterborough
State/Province
Ontario
ZIP/Postal Code
K9H 2P4
Country
Canada
Facility Name
Toronto Memory Program
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M3B 2S7
Country
Canada
Facility Name
Clinique de la Mémoire de l'Outaouais
City
Gatineau
State/Province
Quebec
ZIP/Postal Code
J8T 8J1
Country
Canada
Facility Name
Medica 111
City
Brno
ZIP/Postal Code
602 00
Country
Czechia
Facility Name
Fakultní nemocnice u sv. Anny v Brně (St. Anne's University Hospital)
City
Brno
ZIP/Postal Code
656 91
Country
Czechia
Facility Name
Neuropsychiatrie s.r.o.
City
Praha
ZIP/Postal Code
160 00
Country
Czechia
Facility Name
Vestra Clinics
City
Rychnov Nad Kněžnou
ZIP/Postal Code
51601
Country
Czechia
Facility Name
Hospices Civils de Lyon - Institut du vieillissement
City
Lyon
ZIP/Postal Code
69100
Country
France
Facility Name
Centre Hospitalier Universitaire de Marseille - Hôpital de la Timone
City
Marseille
ZIP/Postal Code
13005
Country
France
Facility Name
CHU De Montpellier - Hôpital Gui De Chauliac
City
Montpellier
ZIP/Postal Code
34295
Country
France
Facility Name
Groupe Hospitalier Saint-Louis, Lariboisière, Fernand Widal
City
Paris
ZIP/Postal Code
75475
Country
France
Facility Name
Centre Hospitalier Universitaire de Rouen
City
Rouen
ZIP/Postal Code
76031
Country
France
Facility Name
Centre Mémoire de Ressources et de Recherche (CM2R) des Hôpitaux Universitaires de Strasbourg
City
Strasbourg
ZIP/Postal Code
67200
Country
France
Facility Name
CHU Toulouse - Centre de Recherche Clinique du Gérontopôle
City
Toulouse
ZIP/Postal Code
31059
Country
France
Facility Name
Uniklinik RWTH Aachen Medizinische Klinik III
City
Aachen
Country
Germany
Facility Name
Klinikum der Universitaet Muenchen Innenstadt
City
München
Country
Germany
Facility Name
Klinik fuer Psychiatrie und Psychotherapie
City
Tübingen
Country
Germany
Facility Name
Studienzentrum Nord-West
City
Westerstede
Country
Germany
Facility Name
Memory Clinic Geriatric Department Landspitali University Hospital
City
Reykjavík
ZIP/Postal Code
101
Country
Iceland
Facility Name
Brain Research Center Amsterdam
City
Amsterdam
ZIP/Postal Code
1081 GN
Country
Netherlands
Facility Name
Brain Research Center Den Bosch
City
Den Bosch
ZIP/Postal Code
5223 LA
Country
Netherlands
Facility Name
Brain Research Center Zwolle
City
Zwolle
ZIP/Postal Code
8025 AZ
Country
Netherlands
Facility Name
Fundacia ACE - Institut Catala de Neurociencies Aplicadas
City
Barcelona
ZIP/Postal Code
08028
Country
Spain
Facility Name
Clinica Universidad de Navarra
City
Madrid
ZIP/Postal Code
28027
Country
Spain
Facility Name
Hospital Clinico San Carlos
City
Madrid
ZIP/Postal Code
28040
Country
Spain
Facility Name
Clinica Universidad de Navarra
City
Pamplona
ZIP/Postal Code
31008
Country
Spain
Facility Name
Hospital Universitari MutuaTerrassa
City
Terrassa
ZIP/Postal Code
08221
Country
Spain
Facility Name
Centro Hospital Universitario Dr. Preset
City
Valencia
ZIP/Postal Code
46017
Country
Spain
Facility Name
Re:Cognition Health
City
Birmingham
ZIP/Postal Code
B16 8LT
Country
United Kingdom
Facility Name
Re:Cognition Health
City
Bristol
ZIP/Postal Code
BS32 4SY
Country
United Kingdom
Facility Name
Re:Cognition Health
City
Guildford
ZIP/Postal Code
GU2 7YD
Country
United Kingdom
Facility Name
St. Pancras Clinical Research
City
London
ZIP/Postal Code
EC2Y 8EA
Country
United Kingdom
Facility Name
Re:Cognition Health
City
London
ZIP/Postal Code
W1G 9JF
Country
United Kingdom
Facility Name
Glasgow Memory Clinic
City
Motherwell
ZIP/Postal Code
ML1 4UF
Country
United Kingdom
Facility Name
Re:Cognition Health
City
Plymouth
ZIP/Postal Code
PL6 8BT
Country
United Kingdom
Facility Name
Re:Cognition Health
City
Winchester
ZIP/Postal Code
SO21 1HU
Country
United Kingdom

12. IPD Sharing Statement

Learn more about this trial

An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects

We'll reach out to this number within 24 hrs